Dr. Yarranton has over 20 years of experience in the biotechnology industry both in Europe and the US. He spent 16 years at Celltech Therapeutics in the UK where he led their research activities. During that time he led a ‘joint venture’ between Celltech and American Cyanamid (later Wyeth) that developed the first approved antibody-drug conjugate, Mylotarg. Dr. Yarranton also designed and developed the bacterially-produced PEGylated anti-TNF antibody Fab fragment (CDP870) currently in Phase III studies for the treatment of rheumatoid arthritis. In 1998, Dr. Yarranton joined Coulter Pharmaceutical where he led the team that refiled the BLA for Bexxar, a radioiodinated antibody for the treatment of relapsed and refractory Non Hodgkin’s Lymphoma. Following the acquisition of Coulter Pharmaceutical by Corixa, Dr. Yarranton became site director of the South San Francisco site and joined Deltagen in May 2002 as Executive Vice President of Research and Development.
